Clinical Trials Browser

Phase 2 × INDUSTRY × RE1-silencing transcription factor × Clear all

NCT00126451 2017-04-10

A Clinical Trial of Oral Suberoylanilide Hydroxamic Acid (SAHA) in Patients With Relapsed or Refractory Breast, Colorectal and Non-Small Cell Lung Cancer (0683-011)(TERMINATED)

Phase 2 Terminated

BreastGastrointestinalThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms